Host defence capacities of pulmonary surfactant: evidence for ‘non‐surfactant’ functions of the surfactant system

European Journal of Clinical Investigation

Volumn 24, Issue 9, 1994, Pages 586-599

  PISON, U ^a   MAX, M ^a   NEUENDANK, A ^a   WEIssBACH S ^a   PIETSCHMANN, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT;

HOST RESISTANCE; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; REVIEW;

ANIMAL; HUMAN; IMMUNITY; LUNG; PULMONARY SURFACTANTS;

EID: 0028060044     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1994.tb01110.x     Document Type: Review

References (170)

1. Surface properties in relation to atelectasis and hyaline membrane disease
2. Artificial surfactant therapy in hyaline membrane disease
3. Surfactant for the treatment of respiratory distress syndrome
4. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol
5. Surfactant abnormalities in patients with respiratory failure after multiple trauma
6. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome
7. Surfactant protein A (SP‐A) is decreased in acute parenchymal lung injury associated with polytrauma
8. Increased recovery of surfactant protein A in AIDS‐related pneumonia
9. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia
10. Surfactant analysis during Pneumocystis carinii pneumonia in HIV‐infected patients
11. Epithelial and surfactant changes in influenzal pulmonary lesions
12. Alveolar stability and phospholipid content in normal pig lungs and in pig lungs with Mycoplasma pneumonia
13. Inhibition of surfactant subtype convertase in radiation model of adult respiratory distress syndrome
14. Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma
15. O2‐ and pneumonia‐induced lung injury. II. Properties of pulmonary surfactant
16. Altered pulmonary surfactant in uncomplicated and septicemia‐complicated courses of acute respiratory failure
17. Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome
18. Decreased surfactant protein A in patients with bacterial pneumonia
19. Neue Auffassung über einen Grundbegriff der Atemmechanik. Die Retraktionskraft der Lunge, abhängig von der Oberflächenspannung in den Alveolen
20. Properties, function and origin of the alveolar lining layer
21. Surface tension of lung extracts
22. Surface lining of lung alveoli
23. Pulmonary surface tension and alveolar stability
24. Direct determination of surface tension in the lung
25. A model for the mechanical structure of the alveolar duct
26. Is airway closure caused by a liquid film instability?
27. Microvascular membrane permeability in high surface tension pulmonary edema
28. Subfractionation of lung surfactant. Implications for metabolism and surface activity
29. Metabolism and turnover of lung surfactant
30. Alveolar surface tension and lung surfactant
31. Surfactant: composition, structure, and metabolism
32. The lung profile: normal pregnancy
33. Lipid synthesis and surfactant turnover in the lungs
34. Surfactant phospholipids: synthesis and storage
35. Isolation and assay of dipalmityl lecithin in lung extracts
36. Pulmonary surfactant: an interdisciplinary approach
37. Phosphatidylglycerol‐deficient lung surfactant has normal properties
38. Identification of the immunosuppressive components of canine pulmonary surface active material
39. A proposed nomenclature for pulmonary surfactant‐associated proteins
40. Purification and biochemical characterization of CP4 (SP‐D), a collagenous surfactant‐associated protein
41. Chemical characterization of lung surfactant apoproteins: amino acid composition, N‐terminal sequence and enzymic digestion
42. Glycosylation and secretion of surfactant‐associated glycoprotein A
43. Aspects of secondary and quaternary structure of surfactant protein A from canine lung
44. Structure of canine pulmonary surfactant apoprotein: cDNA and complete amino acid sequence
45. Isolation and characterization of the human pulmonary surfactant apoprotein gene
46. isolation and characterization of cDNA clones for the 35‐kDa pulmonary surfactant‐associated protein
47. Isolation and sequence of a cDNA clone for the rat pulmonary surfactant‐associated protein (PSP‐A)
48. Structures and properties of the surfactant‐associated proteins
49. Macromolecular organization of natural and recombinant lung surfactant protein SP 28–36. Structural homology with the complement factor Clq
50. Mannose‐binding proteins isolated from rat liver contain carbohydrate‐recognition domains linked to collagenous tails. Complete primary structures and homology with pulmonary surfactant apoprotein
51. Pulmonary surfactant and its components inhibit secretion of phosphatidylcholine from cultured rat alveolar type II cells
52. Surfactant apoprotein Mr = 26000–36000 enhances uptake of liposomes by type II cells
53. Regulation of pulmonary surfactant secretion and clearance
54. Nucleotide and amino acid sequences of pulmonary surfactant protein SP 18 and evidence for cooperation between PS 18 and SP 28–36 in surfactant lipid adsorption
55. Effects of the surfactant‐associated proteins, SP‐A, SP‐B and SP‐C, on phospholipid surface film formation
56. Pulmonary surfactant protein A enhances the host‐defense mechanism of rat alveolar macrophages
57. Pulmonary surfactant‐associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro
58. cDNA and deduced amino acid sequence of human pulmonary surfactant‐associated proteolipid SPL(Phe)
59. Low molecular weight human pulmonary surfactant protein (SP5): isolation, characterization, and cDNA and amino acid sequences
60. Characterization of pulmonary surfactant protein D: its copurification with lipids
61. Surfactant protein D: subcellular localization in nonciliated bronchiolar epithelial cells
62. Primary structure of rat pulmonary surfactant protein D. cDNA and deduced amino acid sequence
63. Purification, characterization and cDNA cloning of human lung surfactant protein D
64. Human surfactant protein D: SP‐D contains a C‐type lectin carbohydrate recognition domain
65. Surfactant protein D (SP‐D) is a divalent cation‐dependent carbohydrate binding protein
66. Immunocytochemical localization and identification of the major surfactant protein in adult rat lung
67. Immunocytochemical localization of the major surfactant apoproteins in type II cells, Clara cells, and alveolar macrophages of rat lungs
68. Ventilation and secretion of pulmonary surfactant
69. Alveolar function following surfactant deactivation
70. Conversion of lamellar body membranes into tubular myelin in alveoli of fetal rat lungs
71. Effects of a surfactant‐associated protein and calcium ions on the structure and surface activity of lung surfactant lipids
72. Uptake of lung surfactant subfractions into lamellar bodies of adult rabbit lungs
73. Rat lung surfactant kinetics: biochemical and morphometric correlation. J Appl Physiol
74. Studies on the fate of pulmonary surfactant in the lung
75. The catabolism of lung surfactant by alveolar macrophages
76. Pulmonary host defense. State of the art
77. Lung defense. The paradox of inflammation
78. Bacterial adherence to respiratory tract mucosa—a dynamic interaction leading to colonization
79. The upper airways. I. Nasal physiology and defence of the lungs
80. The upper airways. II. The larynx and trachea
81. Dynein structure and function
82. Human ciliary beat frequency in epithelium from intrathoracic and extrathoracic airways
83. The propulsion of mucus by cilia
84. Defense mechanisms of the respiratory membrane
85. The normal microbial flora
86. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups
87. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage
88. Characterization of inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease
89. Distribution and function of alveolar cells in multiply injured patients with trauma‐induced ARDS
90. Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects: quantification and comparison with immunoglobulin A and E
91. The class specific immunoglobulin composition of fluids obtained from various levels of the canine respiratory tract
92. Immunoglobulin A: strategic defense initiative at the mucosal surface
93. Immunoglobulin A: molecular and cellular interactions involved in IgA biosynthesis and immune response
94. Complement activity in normal rabbit bronchoalveolar fluid
95. Integrated host defense against infections
96. Opsonin‐independent phagocytosis by human alveolar macrophages: augmentation by human plasma fibronectin
97. Production of fibronectin by the human alveolar macrophage: a mechanism for the recruitment of fibroblasts to sites of tissue injury in the interstitial lung diseases
98. Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis
99. Role of iron in microbe‐host interactions
100. Granulocyte‐alveolar‐macrophage interaction in the pulmonary clearance of Staphylococcus aureus
101. A morphological study of the role of phagocytes in the clearance of Staphylococcus aureus from the lung
102. Leukocytic response to inhaled bacteria
103. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice
104. Deficiency in host defense
105. The immotile‐cilia syndrome. A congenital ciliary abnormality as an etiologic factor in chronic airway infections and male sterility
106. Disorders of phagocytic cells
107. Acquired immune deficiency syndrome and the lung
108. Complement. Molecular Genetics
109. The effect of complement depletion on lung clearance of bacteria
110. Primary immunodeficiency diseases
111. Isolation and culture of alveolar type II cells
112. The role of the alveolar macrophage in the clearance of bacteria from the lung
113. Enhancement of bactericidal capacity of alveolar macrophages by human alveolar lining material
114. Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material
115. Rat lung lavage surfactant enhances bacterial phagocytosis and intracellular killing by alveolar macrophages
116. Immunosuppressive activity of canine pulmonary surface active material
117. Effect of rat alveolar lining material on macrophage receptors
118. Effect of rat surfactant lipids on complement and Fc receptors of macrophages
119. Augmentation of rat alveolar macrophage migration by surfactant protein
120. Enhanced luminol‐dependent chemiluminescence of stimulated rat alveolar macrophages by pretreatment with alveolar lining materials
121. The effect of pulmonary surface‐active material on the generation and expression of murine B‐ and T‐lymphocyte effector functions in vitro
122. Human lung lavage surfactant enhances staphylococcal phagocytosis by alveolar macrophages
123. Human alveolar lining material and antibacterial defenses
124. Chemotactic and candidacidal responses of rabbit alveolar macrophages during postnatal development and the modulating roles of surfactant in these responses
125. Surfactant therapy of newborn rabbits impairs lung macrophage bactericidal activity
126. Morphology and function of blood monocytes after incubation with lung surfactant
127. Specific binding of surfactant apoprotein SP‐A to rat alveolar macrophages
128. Interaction of Clq receptor with lung surfactant protein A
129. Oxygen metabolites from phagocytes
130. Effect of canine surfactant protein (SP‐A) on the respiratory burst of phagocytic cells
131. Pulmonary surfactant inhibits priming of rabbit alveolar macrophage. Evidence that surfactant suppresses the oxidative burst of alveolar macrophages in infant rabbits
132. Effects of pulmonary surfactant and surfactant protein A on phagocytosis of fractionated alveolar macrophages: relationship to starvation
133. Surfactant protein A (SP‐A) enhances the production of reactive oxygen species in alveolar macrophages
134. Signal transduction mechanisms of Clq‐mediated superoxide production. Evidence for the involvement of temporally distinct staurosporine‐insensitive and sensitive pathways
135. Lung surfactant protein A (SP‐A) enhances serum‐independent phagocytosis of bacteria by alveolar macrophages
136. Surfactant protein A (SP‐A) stimulates phagocytosis of candida trop. by alveolar macrophages
137. Phagocytic functions and tumour necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf)
138. Human pulmonary surfactant protein (SP‐A), a protein structurally homologous to Clq, can enhance FcR‐ and CR1‐mediated phagocytosis
139. An immobile subset of plasma membrane CD11b/CD18 (Mac‐1) is involved in phagocytosis of targets recognized by multiple receptors
140. Pulmonary surfactant protein A stimulates chemotaxis of alveolar macrophages
141. Phospholipid binding and biophysical activity of pulmonary surfactant‐associated protein (SAP)‐35 and its non‐collagenous COOH‐terminal domains
142. Binding of calcium to SP‐A, a surfactant‐associated protein
143. The major lung surfactant protein, SP 28–36, is a calcium‐dependent, carbohydrate‐binding protein
144. Specificity of lung surfactant protein SP‐A for both the carbohydrate and the lipid moieties of certain neutral glycolipids
145. Structural comparison of recombinant pulmonary surfactant protein SP‐A derived from two human coding sequences: implications for the chain composition of natural human SP‐A
146. Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages
147. Canine surface active material and pulmonary lymphocyte function studies with mixed‐lymphocyte culture
148. Pulmonary surfactant suppresses the immune lung injury response to inhaled antigen in guinea pigs
149. Enhancement of macrophage and monocyte cytotoxicity by the surface active material of lung lining fluid
150. Synthetic surfactant (Exosurf) inhibits endotoxin‐stimulated cytokine secretion by human alveolar macrophages
151. Tumor necrosis factor‐alpha inhibits expression of pulmonary surfactant protein
152. Interferon‐gamma and synthesis of surfactant components by cultured human fetal lung
153. An experimental investigation of the role of the body fluids in connection with phagocytosis
154. Receptors for complement and the biology of phagocytosis
155. Collectins: pattern recognition molecules involved in first line host defense
156. Two distinct classes of carbohydrate‐recognition domains in animal lectins
157. 120‐kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A
158. Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages
159. Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages
160. Binding of surfactant protein A (SP‐A) to herpes simplex virus type 1‐infected cells is mediated by the carbohydrate moiety of SP‐A
161. Interactions of surfactant protein D with bacterial lipopolysaccharides
162. The collagenous domains of macrophage scavenger receptors and complement component Clq mediate their similar, but not identical, binding specificies for polyanionic ligands
163. Complexing of bacterial lipopolysaccharide with lung surfactant
164. Platelet‐activating factor in surfactant preparations [see comments]
165. Surfactant‐mucus interaction
166. Surface forces displace particles deposited in airways toward the epithelium
167. Pulmonary surfactant: surface properties and function of alveolar and airway surfactant
168. Effect of artificial surfactant on ciliary beat frequency in guinea pig trachea